Today: 18 March 2026
Standard Chartered share price climbs ahead of BoE as STAN.L hovers near 52-week high
4 February 2026
1 min read

Standard Chartered share price climbs ahead of BoE as STAN.L hovers near 52-week high

London, Feb 4, 2026, 09:06 GMT — Regular session

  • STAN.L climbed roughly 1.2% in early London trading, nearing its recent peak levels
  • Investors are focused on the Bank of England’s decision set for Thursday
  • Standard Chartered will release full-year results on Feb. 24, followed by a briefing for investors led by the CEO and CFO

Standard Chartered shares climbed on Wednesday, holding near the upper end of their recent range as investors weighed central bank risks against a weak mood in European stocks. Around 09:05 GMT, the stock was up roughly 1.2% at 1,901.5 pence, after closing at 1,879.0 pence the day before. Trading during the session fluctuated between 1,888.5 and 1,910.0 pence. Investing.com

The stock continued its streak after hitting a fresh 52-week high on Monday, climbing 2.36% to 19.06 pounds, according to MarketWatch data. That day’s trading volume was 2.1 million shares, noticeably under the 50-day average of 4.6 million. MarketWatch

Timing is key. London stocks took a hit from a sharp sell-off in AI-linked software and data-analytics firms as traders brace for the Bank of England’s Thursday policy announcement, where rates are widely expected to stay at 3.75%. “Risk appetite just isn’t fully restored,” noted Ipek Ozkardeskaya, senior analyst at Swissquote Bank. Reuters

Stocks in Europe held steady on Wednesday morning, with declines in healthcare balancing out gains in the energy sector. Investors were focused on upcoming euro zone inflation figures due later in the day. Reuters

UK lenders drew attention following a Reuters report that Lloyds intends to ramp up its corporate and institutional banking efforts. This strategy has intensified scrutiny on the sources of bank growth as policy rates near their peak. Reuters

Standard Chartered is eyeing several key dates ahead. According to its investor relations page, the bank plans to publish Q4 and full-year 2025 results at 04:00 UK time on Feb. 24, followed by a presentation from CEO Bill Winters and CFO Diego De Giorgi later that morning. Additionally, it flagged new press releases on Feb. 3, highlighting an “AI bubble meter” featured in an equities newsletter. Standard Chartered Bank

Investors will zero in on key metrics: income momentum, credit costs, and management’s outlook for the coming year. With the stock having already seen a sharp rerating, even subtle shifts in tone could tweak the tape.

The rally isn’t without risks. A sudden change in central bank signals or fresh risk-off moves sparked by the AI-fueled tech selloff could push recent highs to the test sooner rather than later, particularly if volatility remains high.

Traders are now eyeing Thursday’s Bank of England announcement. After that, the focus shifts to Standard Chartered’s results on Feb. 24, looking for clues on earnings strength and capital allocation.

Stock Market Today

  • Boyd Group Services Inc. Q4 Earnings Beat Estimates with $0.90 EPS
    March 18, 2026, 9:11 AM EDT. Boyd Group Services Inc. (BGSI) reported fourth-quarter earnings of $0.90 per share, surpassing the Zacks Consensus Estimate of $0.63 by 42.86%, and up from $0.29 a year ago. Revenue for the quarter came in at $793.85 million, missing estimates by 3.39% but up from last year's $752.34 million. BGSI has outperformed the S&P 500 so far in 2025, rising 1.5% compared to a 1.9% decline. Despite mixed recent revisions to earnings estimates, the stock holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market. Investors will focus on management's commentary and the trend in earnings forecasts for upcoming quarters to gauge the stock's future direction in the consumer staples sector.
GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook
Previous Story

GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%
Next Story

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Go toTop